Close

BIO Applauds President Trump's Directive to Allow Sales of E15 Fuel Year-Round

Oct 9 2018
The following statement may be attributed to Brent Erickson, BIO’s Executive Vice President, Industrial and Environmental Section, in response to President Donald Trump’s directive allowing the sale of E15 fuels year-round. 

BIO Statement on the United States-Mexico-Canada Agreement

Oct 4 2018

Washington, D.C. (October 4, 2018) – Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the United States-Mexico-Canada...

BIO Joins Alliance to Protect Medical Innovation

Oct 4 2018
"Innovation and bad public policy cannot coexist. That’s an important message often neglected in the debate about health care costs, and that’s precisely the message this organization will help deliver.”

BIO Applauds House Passage of the American Innovation Act

Sep 27 2018
Bill reforms tax rules that currently penalize investment in job creation, innovation   Washington, DC (September 27, 2018) – The Biotechnology Innovation Organization (BIO) today applauded the House of Representatives for passing the American Innovation Act of 2018 (H.R. 6756), which includes a provision that would protect investments in start-ups from inadvertently triggering the net operating loss (NOL) limitations under Section 382 of the tax code. R&D-intensive biotech start-ups frequently accumulate substantial NOLs in their early, pre-revenue years, given their typical reliance on investor capital for more than a decade before realizing any product revenue.

BIO Praises Passage of Small Business Innovation Protection Act

Sep 26 2018

Washington, D.C. (September 26, 2018) – The Biotechnology Innovation Organization applauds the House and Senate’s bipartisan passage of the Small Business Innovation Protection Act. The bill...

BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018

Sep 25 2018
Legislation will strengthen pipeline of medical countermeasures against serious public health threats   Washington, DC (September 25, 2018) – The Biotechnology Innovation Organization (BIO) today applauds the House of Representatives for passing the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (H.R. 6378). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS).  

BIO Applauds Release of New National Biodefense Strategy

Sep 19 2018
“I applaud the Administration for recognizing the importance of strengthening our national biodefense and preparedness efforts. Our nation continues to face a wide range of biological threats, and this strategy is an important step in the right direction."

BIO Applauds Senate Passage of Opioid Crisis Response Act of 2018

Sep 17 2018
“BIO’s member companies are committed to unleashing the power of scientific innovation to develop solutions that will lead to an America free of prescription opioid addiction. Today’s vote advances vital legislation that will help get new innovations to patients suffering from pain and addiction, by ensuring that our research and regulatory environments keep pace with our accelerating scientific knowledge and capabilities."

BIO Applauds Legislation to Spur Investment in Start-ups

Sep 12 2018
Washington, DC (September 12, 2018) – The Biotechnology Innovation Organization (BIO) today applauded the introduction of the American Innovation Act of 2018 (H.R. 6756), which includes a provision that would protect investments in start-ups from inadvertently triggering the net operating loss (NOL) limitations under Section 382 of the tax code. R&D-intensive biotech start-ups frequently accumulate substantial NOLs in their early, pre-revenue years, given their typical reliance on investor capital for more than a decade before realizing any product revenue.

BIO Announces Programming for the 17th Annual BIO Investor Forum

Sep 4 2018
Amidst a healthy investment climate for biotech companies, BIO announces programming for the 17th annual BIO Investor Forum